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Michael Ezrokhi, Shuqin Luo, Yelena Trubitsyna and Anthony H. Cincotta*Erratum
After publication of this manuscript [1], we noted errors
to the labels of Fig. 7. The Y-axis of panel C was incor-
rectly labelled as “Plasma Adiponectin, ng/ml” instead of
“PEPCK, % of Vehicle”. (Please see a corrected version
of Fig. 7 below).
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Fig. 7 Impact of timed daily bromocriptine or vehicle administration on gluconeogenic pathway regulators – FOXO1 phosphorylated at Ser256
(Panel a), glucose-6-phosphatase (Panel b), and PEPCK (Panel c). Proteins we quantified by Western blotting. Values are means ± SEM of 8 animals
in each group. *Difference is statistically significant; P values are noted under each panel
Ezrokhi et al. Diabetology & Metabolic Syndrome  (2015) 7:61 Page 2 of 2
